L

Lepu Scientech Medical Technology Shanghai Co Ltd
HKEX:2291

Watchlist Manager
Lepu Scientech Medical Technology Shanghai Co Ltd
HKEX:2291
Watchlist
Price: 17.36 HKD 0.64% Market Closed
Market Cap: 6B HKD

Profitability Summary

Lepu Scientech Medical Technology Shanghai Co Ltd's profitability score is 66/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

66/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

66/100
Profitability
Score
66/100
Profitability
Score

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Lepu Scientech Medical Technology Shanghai Co Ltd

Revenue
552.2m CNY
Cost of Revenue
-70.5m CNY
Gross Profit
481.7m CNY
Operating Expenses
-174.1m CNY
Operating Income
307.7m CNY
Other Expenses
-20.3m CNY
Net Income
287.4m CNY

Margins Comparison
Lepu Scientech Medical Technology Shanghai Co Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
Lepu Scientech Medical Technology Shanghai Co Ltd
HKEX:2291
6B HKD
87%
56%
52%
US
Abbott Laboratories
NYSE:ABT
222.8B USD
56%
18%
32%
US
Intuitive Surgical Inc
NASDAQ:ISRG
201.3B USD
66%
29%
29%
US
Boston Scientific Corp
NYSE:BSX
143.6B USD
69%
19%
14%
US
Stryker Corp
NYSE:SYK
140.8B USD
65%
22%
12%
IE
Medtronic PLC
NYSE:MDT
129.7B USD
66%
19%
14%
US
IDEXX Laboratories Inc
NASDAQ:IDXX
58.1B USD
62%
31%
25%
US
Becton Dickinson and Co
NYSE:BDX
55.2B USD
45%
14%
8%
DE
Siemens Healthineers AG
XETRA:SHL
46.9B EUR
39%
14%
9%
US
Edwards Lifesciences Corp
NYSE:EW
49.4B USD
78%
28%
23%
US
Resmed Inc
NYSE:RMD
36.6B USD
60%
33%
27%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Lepu Scientech Medical Technology Shanghai Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
Lepu Scientech Medical Technology Shanghai Co Ltd
HKEX:2291
6B HKD
15%
13%
16%
30%
US
Abbott Laboratories
NYSE:ABT
222.8B USD
31%
18%
12%
20%
US
Intuitive Surgical Inc
NASDAQ:ISRG
201.3B USD
17%
15%
17%
22%
US
Boston Scientific Corp
NYSE:BSX
143.6B USD
13%
7%
11%
9%
US
Stryker Corp
NYSE:SYK
140.8B USD
14%
6%
14%
12%
IE
Medtronic PLC
NYSE:MDT
129.7B USD
10%
5%
9%
7%
US
IDEXX Laboratories Inc
NASDAQ:IDXX
58.1B USD
65%
31%
58%
35%
US
Becton Dickinson and Co
NYSE:BDX
55.2B USD
7%
3%
6%
5%
DE
Siemens Healthineers AG
XETRA:SHL
46.9B EUR
12%
5%
10%
6%
US
Edwards Lifesciences Corp
NYSE:EW
49.4B USD
14%
10%
14%
16%
US
Resmed Inc
NYSE:RMD
36.6B USD
25%
19%
26%
22%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less